NCT07136727Not yet recruiting
AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)
The Impact of Multimodal Digital Fusion AI-Assisted Decision Support System-Based Comprehensive Management on Clinical Outcomes in County-Level Patients With Comorbid Cancer:A Prospective Non-randomized Controlled Interventional Study.
Source: ClinicalTrials.gov · Last updated 22 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 5000 (estimated)
- First submitted
- 9 Aug 2025
- Start date
- 15 Aug 2025
- Primary completion date
- 1 May 2027
- Lead sponsor
- The First Affiliated Hospital of Xinxiang Medical College
- Diseases
- High blood pressure
- NCT number
- NCT07136727
What you commit to
- Study type: Interventional
- Planned participants: 5000
- From 15 Aug 2025 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness;
Other
- Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme;
- Women during pregnancy or lactation；
- Have participated in other interventional studies in the past 1 month or are currently participating;
- Patients with ECOG ≥ 3 that do not respond to treatment;
- Patients with an expected survival of \< 3 months that do not respond to treatment;
- Cases deemed unsuitable for enrollment by the investigator.
Who the study is looking for
- Patients with a definite diagnosis of malignancy by histopathology and/or cytology;
- Age ≥18 years;
- There is no gender limit
- Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ;
- Conscious and able to answer questions and use electronic devices autonomously;
- Patients were able to understand the study and voluntarily sign an informed consent form;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Xinxiang Medical University Coordinator of this site? Confirm its status | Xinxiang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.